“oral”的搜索结果，显示 141-150 项，共有 4138 项

1. 成釉细胞瘤- 症状与病因- 妙佑医疗国际

   Effiom OA, et al. Ameloblastoma: Current etiopathological concepts and management. Oral Diseases. 2018; doi:10.1111/odi.12646. Flint PW, et al., eds ...

2. 唇癌- 症状与病因- 妙佑医疗国际

   AskMayoExpert. Oral cavity carcinoma, stages I to IV: Diagnosis to first treatment (adult). Mayo Clinic; 2017. Head and neck cancers. National Comprehensive ...

3. 心血管医学- 临床试验- 妙佑医疗国际

   ... (Oral Anti-Platelet) agents. In addition to exploring ED treatment patterns and success of both ischemic and bleeding risk stratification prior to definition ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B LLy) ...

5. 血液科- 临床试验- 妙佑医疗国际

   ... (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on Day 1 of each 28-day cycle (Cycle 1: 375 mg/m2; Cycles 2-6 ...

6. 血液科- 临床试验- 妙佑医疗国际

   ... (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on Day 1 of each 28-day cycle (Cycle 1: 375 mg/m2; Cycles 2-6 ...

7. 心血管医学- 临床试验- 妙佑医疗国际

   ... (Oral Anti-Platelet) agents. In addition to exploring ED treatment patterns and success of both ischemic and bleeding risk stratification prior to definition ...

8. 外科 - 医生 - 妙佑医疗国际

   ... Oral biopsy, Cancer, Head and neck cancer, Facial fracture, Osteoradionecrosis, Chondrosarcoma, Nasal and paranasal tumors, Thyroid cancer, Soft tissue ...

9. 血液科- 临床试验- 妙佑医疗国际

   ... (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on Day 1 of each 28-day cycle (Cycle 1: 375 mg/m2; Cycles 2-6 ...

10. 阻生智齿- 医生与科室- 妙佑医疗国际

    显示$起始范围- $结束范围/源自可用$可用医生. James M. Van Ess, M.D., D.D.S.. Oral ...